AlloVir CEO Departs, CFO Steps In

Dow Jones
2024-12-21

By Katherine Hamilton

AlloVir said its chief executive Diana Brainard is departing and the company has appointed its CFO to take her place.

Brainard's departure became effective Thursday and she resigned as director of the cell therapy company, the company said on Friday. Her resignation did not result from any disagreement with the company related to its operations, policies or practices, AlloVir said.

AlloVir said it plans to give Brainard a lump sum in cash worth 36 months of her base salary, which was $623,432 in 2023, according to a filing. She is also set to receive $100,000 for completing the proposed merger with Kalaris Therapeutics.

To succeed Brainard, AlloVir appointed Vikas Sinha, who has been serving as chief financial officer since 2019. Sinha, 61, co-founded ElevateBio and was previously CFO of Alexion Pharmaceuticals.

Sinha' earned a total compensation of $2.9 million as CFO in 2023. Brainard made a total of $6.1 million as CEO that year.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 20, 2024 17:40 ET (22:40 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10